Cancer Letters Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Cancer Letters author guidelines.

Use this page when deciding:

• whether the cancer-biology contribution is mechanistic
• whether functional validation is rigorous
• whether translational relevance is direct

• a clear cancer-biology mechanism contribution
• rigorous functional validation
• in-vivo or clinical validation
• translational relevance
• a cover letter establishing the cancer-biology contribution

• Descriptive observations without mechanism.
• Weak functional validation.
• Missing in-vivo or clinical validation.
• Drug discovery without cancer-biology focus.

Cancer Letters is a flagship cancer-research journal.

Mechanism + translational standard: the journal differentiates from Cancer Research (broader) and specialty cancer journals by demanding cancer-biology mechanism with translational relevance.

Functional-validation expectation: editors expect mutants, knockouts, or comparable functional evidence.

The 40-50% desk rejection rate: decisive editorial screen.

The strongest Cancer Letters cover letters establish:

• the cancer-biology mechanism contribution
• the functional validation
• the in-vivo or clinical evidence
• the translational relevance

• Is Cancer Letters a good journal?

Before upload, run your manuscript through a Cancer Letters mechanism readiness check.

In our pre-submission review work with cancer manuscripts targeting Cancer Letters, three patterns generate the most consistent desk rejections.

In our experience, roughly 35% of Cancer Letters desk rejections trace to descriptive observations without mechanism. In our experience, roughly 25% involve weak functional validation. In our experience, roughly 20% arise from missing in-vivo or clinical validation.

• Descriptive observations without functional cancer-biology studies. Cancer Letters editors look for mechanism, not just observations. We observe submissions reporting expression patterns or correlations without functional validation routinely desk-rejected.

• Weak functional validation. Editors expect mutants, knockouts, knockdowns, or comparable functional evidence. We see manuscripts with thin functional experiments routinely returned.

• Missing in-vivo or clinical validation. Cancer Letters specifically expects animal models or patient samples. We find papers reporting only cell-culture data without in-vivo or clinical evidence routinely declined. A Cancer Letters mechanism readiness check can identify whether the package supports a submission.

Clarivate JCR 2024 bibliometric data places Cancer Letters among top cancer-research journals.

In pre-submission diagnostic work for top cancer-research journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must be mechanistic, not descriptive. Second, functional validation should include mutants, knockouts, or comparable experiments. Third, in-vivo or clinical validation should be included. Fourth, translational relevance should be direct.

The single most consistent feedback class we deliver in pre-submission diagnostics for Cancer Letters is the descriptive-versus-mechanistic distinction. Cancer Letters editors expect mechanism, not just expression or correlation observations. Submissions framed as "we observed expression of X in cancer Y" routinely receive "where is the mechanism?" feedback during desk screening. We coach authors to lead with the mechanism question and frame the observation in service of that question. Papers framed as "we tested whether X drives cancer phenotype Y by combining functional, in-vivo, and patient-sample analysis" receive better editorial traction. The same logic applies across mechanism-focused cancer journals: editors are operating with limited slot inventory, and the submissions that get traction lead with the mechanism question.

Beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Cancer Letters. First, manuscripts where the abstract reports observations without articulating the cancer-biology mechanism are flagged at desk for descriptive framing. We recommend the abstract's central sentences state the mechanism question, the experimental approach, and the mechanistic finding. Second, manuscripts where in-vivo data is reported only in supplementary materials are flagged for translational framing gaps. We recommend integrating in-vivo data into main figures. Third, manuscripts that lack engagement with Cancer Letters' recent issues are at risk of being told the contribution doesn't fit the publication conversation.

The strongest manuscripts we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page and use it to make the case for fit, contribution, and significance, not to summarize the abstract. Second, they include a one-sentence elevator pitch in the cover letter's opening that the editor can use when discussing the manuscript internally. Third, they identify the specific recent papers in the journal that this manuscript builds on and the specific competing or contradicting work; this signals the authors are operating inside the publication conversation rather than outside it.